Press Releases Imugene Limited

Equities

IMU

AU000000IMU9

Delayed Australian S.E. Other stock markets 10:00:48 2024-04-30 pm EDT			5-day change	1st Jan Change
0.0835 ^AUD	-4.02%		-1.18%	-23.64%

Apr. 16	Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	MT
Apr. 16	Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million	Apr. 16	AQ
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort	Apr. 15	AQ
Imugene opens enrolment for Bile Tract Cancer expansion study	Apr. 15	AQ
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024	Apr. 09	AQ
Imugene progresses onCARlytics solid tumour trial to combination arm	Mar. 11	AQ
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment	Mar. 11	AQ
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts	Feb. 22	AQ
Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial	Feb. 15	AQ
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs	Jan. 23	AQ
Imugene Limited - VAXINIA MAST oncolytic virus Phase 1 trial doses first patients in higher dose cohorts	Jan. 19	AQ
Imugene to commence new phase 2 PD1-Vaxx bowel cancer trial	Dec. 06	AQ
Imugene thrilled as VAXINIA granted FDA Fast Track designation	Nov. 28	AQ
Imugene says Azer-cel could be best-in-class Allogeneic CAR T	Nov. 13	AQ
Imugene sees positive early signals in Phase 1 VAXINIA study	Nov. 06	AQ
Imugene thrilled as first patient dosed in Phase 1 OASIS trial	23-10-26	AQ
Imugene welcomes positive FDA feedback on new manufacturing process for azer-cel	23-09-11	AQ
Imugene talks VAXINIA MAST trial and corporate ambition	23-09-04	AQ
Imugene doses first patient in PD1-Vaxx combination trial	23-06-01	AQ
Imugene secures IND approval for first-in-class onCARlytics trial	23-05-19	AQ
Imugene begins dosing in cohort three of VAXINIA monotherapy dose escalation trial	23-04-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Imugene Limited

Equities

IMU

AU000000IMU9

Press Releases

Filters